AEGLEA BIOTHERAPEUTICS INC's ticker is AGLE and the CUSIP is 00773J103. A total of 80 filers reported holding AEGLEA BIOTHERAPEUTICS INC in Q3 2021. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $355,000 | +80.2% | 154,175 | +270.4% | 0.00% | – |
| Q4 2021 | $197,000 | -92.2% | 41,624 | -86.8% | 0.00% | -100.0% |
| Q3 2021 | $2,511,000 | -44.6% | 315,823 | -51.5% | 0.01% | -52.4% |
| Q2 2021 | $4,534,000 | -51.9% | 651,403 | -45.3% | 0.02% | -51.2% |
| Q1 2021 | $9,435,000 | -3.6% | 1,191,239 | -4.2% | 0.04% | -18.9% |
| Q4 2020 | $9,784,000 | +11.1% | 1,243,250 | +0.1% | 0.05% | -5.4% |
| Q3 2020 | $8,809,000 | -23.7% | 1,242,427 | -0.5% | 0.06% | -30.9% |
| Q2 2020 | $11,552,000 | +195.4% | 1,248,915 | +48.8% | 0.08% | +107.7% |
| Q1 2020 | $3,911,000 | -38.6% | 839,160 | +0.7% | 0.04% | -11.4% |
| Q4 2019 | $6,367,000 | +3.4% | 833,407 | +4.1% | 0.04% | -8.3% |
| Q3 2019 | $6,157,000 | +36.4% | 800,607 | +21.5% | 0.05% | +29.7% |
| Q2 2019 | $4,513,000 | -25.4% | 658,698 | -12.4% | 0.04% | +27.6% |
| Q1 2019 | $6,052,000 | – | 751,806 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Yu Fan | 112,044 | $532,000 | 6.17% |
| Aisling Capital Management LP | 1,691,151 | $8,033,000 | 2.83% |
| Bain Capital Life Sciences Investors, LLC | 2,847,689 | $13,527,000 | 1.07% |
| GREAT POINT PARTNERS LLC | 910,251 | $4,324,000 | 0.96% |
| Samsara BioCapital, LLC | 883,720 | $4,198,000 | 0.81% |
| Sio Capital Management, LLC | 498,500 | $2,368,000 | 0.71% |
| UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO | 245,678 | $1,167,000 | 0.53% |
| Nantahala Capital Management | 2,813,560 | $13,364,000 | 0.47% |
| Altium Capital Management LP | 293,764 | $1,395,000 | 0.38% |
| Lion Point Capital, LP | 300,000 | $1,425,000 | 0.38% |